NMLSF - Nova Mentis gets required U.S. DEA export approval for its psilocybin drug NM-1001

Nova Mentis Life Science (OTCQB:NMLSF) on Tuesday said it had got a required export approval from the U.S. Drug Enforcement Administration for its psilocybin drug NM-1001. The drug has been exported and received at Canada's Toronto Institute of Pharmaceutical Technology, where it will be used in a planned phase 2a trial for the treatment of fragile X syndrome, a genetic disorder which causes intellectual disability. The successful import of NM-1001 into Canada "allows (OTCQB:NMLSF) to move forward with the formulation and final production of microdose capsules in preparation for our clinical trial application submission to Health Canada," said NMLSF CEO Will Rascan. Earlier this year, NMLSF announced that a very low microdose formulation of NM-1001 significantly modulated behavioral and cognitive defects, such as recognition memory, in a genetic model of fragile X syndrome. Psilocybin is the psychedelic active compound in magic mushrooms. Several biotech companies have been looking into its use

For further details see:

Nova Mentis gets required U.S. DEA export approval for its psilocybin drug NM-1001